SCHEMBL21296924

SCHEMBL21296924

Cc1cc(Oc2[nH]nnc2C(=O)O)ccc1Cl

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 4/20 0.46
ALDH1A1 P00352 3/20 0.41
HAO1 Q9UJM8 2/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
MAPT P10636 2/20 0.40
ALPL P05186 1/20 0.40
ALPI P09923 1/20 0.40
ALPG P10696 1/20 0.40
KDM4E B2RXH2 2/20 0.39
POLB P06746 2/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
PKM P14618 1/20 0.39
ICAM1 P05362 1/20 0.38
SELE P16581 1/20 0.38
BCL2 P10415 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
SENP2 Q9HC62 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29799135 0.88 KMO (0.48) ALDH1A1HAO1MRGPRX4KDM4E
SCHEMBL21296869 0.88 KMO (0.48) ALDH1A1HAO1MRGPRX4KDM4E
SCHEMBL29799130 0.88 HAO1 (0.43) ALDH1A1HAO1MAPTALPLKDM4E
SCHEMBL21296933 0.88 HAO1 (0.43) ALDH1A1HAO1MAPTALPLKDM4E
SCHEMBL21296971 0.84 HAO1 (0.41) HAO1ALPLICAM1SELE
SCHEMBL21296923 0.84 HAO1 (0.41) HAO1
SCHEMBL21296865 0.84 HAO1 (0.43) HAO1MAPTPOLBKMT2AMEN1
SCHEMBL23001948 0.82 HAO1 (0.52) HAO1
SCHEMBL21296902 0.82 SOS1 (0.41) HAO1MAPTALPL
SCHEMBL23319976 0.82 HAO1 (0.38) HAO1MAPTKMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11389456-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-07-19 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, LOX MCL1 3573/4885ALDH1A1 543/4885HAO1 14/4885
US-11389456-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, LOX MCL1 3573/4885ALDH1A1 543/4885HAO1 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.